HAG
SBBP

HighPoint Advisor Group’s Strongbridge Biopharma plc. SBBP Stock Holding History

HighPoint Advisor Group’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,000
Closed -$29K – 575
2021
Q1 		$29K Buy
+11,000
New +$33.2K ﹤0.01% 498

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

HighPoint Advisor Group's SBBP Position: Q2 2021 in Review

HighPoint Advisor Group sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 11,000 shares — an estimated $29K sold.

HighPoint Advisor Group first reported a position in SBBP in Q1 2021 and held it in 1 quarter. The position peaked at $29K in Q1 2021. 59 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

  • HighPoint Advisor Group reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
  • HighPoint Advisor Group sold 11,000 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $29K.
  • HighPoint Advisor Group first reported a position in Strongbridge Biopharma plc. in Q1 2021 and held it in 1 quarter.
  • HighPoint Advisor Group's Strongbridge Biopharma plc. position peaked at $29K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on HighPoint Advisor Group's 13F filing for Q2 2021, filed 29 Jul 2021.